0263山師さん@トレード中2020/05/28(木) 08:17:04.34ID:h0gZiSQx0 ちょっと待ってくださいよお 0264山師さん@トレード中2020/05/28(木) 09:19:15.73ID:1F7yRVbr0>>263はオレがおいてきた 修行はしたがハッキリいってこの闘いにはついていけない… 0265山師さん@トレード中2020/05/28(木) 09:25:00.63ID:TsDw0Fc20 貫禄のマイテン笑 0266山師さん@トレード中2020/05/28(木) 10:03:05.98ID:wC2+ViNZ0>>265 空売り外資様を舐めんなよ 0267山師さん@トレード中2020/05/28(木) 10:20:09.71ID:MfwMPLOo0 もういやっ 0268山師さん@トレード中2020/05/28(木) 10:22:08.24ID:TsDw0Fc20 今日は一方通行だね笑 0269山師さん@トレード中2020/05/28(木) 10:38:17.98ID:qhFeg2eLM もう待てねー 0270山師さん@トレード中2020/05/28(木) 10:50:17.38ID:TsDw0Fc20 プラテン拒否笑 まぁ明日出尽くすわけだから今日買う奴なんかいないよな笑 0271山師さん@トレード中2020/05/28(木) 10:51:18.48ID:wC2+ViNZ0>>270 空売り外資様を舐めんなよ 0272山師さん@トレード中2020/05/28(木) 10:54:26.68ID:/26UrNqm0 舐めダルマ来てんね 0273山師さん@トレード中2020/05/28(木) 11:01:49.43ID:TsDw0Fc20 底抜けキター笑 0274山師さん@トレード中2020/05/28(木) 11:06:39.89ID:2+Ib5JrId 誰も期待してないな 0275山師さん@トレード中2020/05/28(木) 11:15:43.34ID:TsDw0Fc20 ここまで期待上げしてたからね 出尽くしでどれくらい下がるかな 2割引きくらいかなたぶん 0276山師さん@トレード中2020/05/28(木) 11:18:03.82ID:wC2+ViNZ0>>273 空売り外資様を舐めんなよ 0277山師さん@トレード中2020/05/28(木) 11:18:40.83ID:TsDw0Fc20 超絶バブル相場の中ここだけ1人バブル崩壊笑 癒されるね笑 0278山師さん@トレード中2020/05/28(木) 11:27:01.98ID:2+Ib5JrId 1700割れそう 0279山師さん@トレード中2020/05/28(木) 11:45:43.34ID:MNjP8PIc0 ちょい待って下さいよぉ… 0280山師さん@トレード中2020/05/28(木) 12:38:01.12ID:TsDw0Fc20 いやー気持ちいいね笑 0281山師さん@トレード中2020/05/28(木) 12:42:45.59ID:wC2+ViNZ0>>278 空売り外資様を舐めんなよ 0282山師さん@トレード中2020/05/28(木) 12:58:01.82ID:2+Ib5JrId 1700わった 0283山師さん@トレード中2020/05/28(木) 13:07:14.93ID:wC2+ViNZ0>>282 空売り外資様を舐めんなよ 空売り外資様を怒らせたらこうなるんやぞ 0284山師さん@トレード中2020/05/28(木) 14:17:21.26ID:/26UrNqm0 QVM国内承認、出て来いやー 0285山師さん@トレード中2020/05/28(木) 18:02:58.14ID:bhuRII5U0 Heptares Patent update: ・・・ 米※国特許出願(Heptares):"Oxime Compounds as Agonists of The Muscarinic M1 and/or M4 Receptor". (5/28公開) ・Document Type and Number: United States Patent Application 20200165220 A1. ・Publication Date: 2020/05/28. ・Assignee: Heptares Therapeutics Limited. Abstract: This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (I) where p; q; X1; X2; Y; R1; R2; R3; R4; R5 and R6 are as defined herein. http://www.freepatentsonline.com/20200165220.pdf0286山師さん@トレード中2020/05/28(木) 18:03:35.72ID:bhuRII5U0 業績予想更新: ・・・ ※四季報(東洋経済):そーせいグループ【業績予想】:(3/16更新) ・2020年12月期予想:売上高10,300百万円、営業利益 ,500百万円、税前利益 ,650百万円、当期利益1,550百万円、1株益 20.1円 ・2021年12月期予想:売上高11,500百万円、営業利益1,000百万円、税前利益1,200百万円、当期利益2,000百万円、1株益 25.9円 ↓ ※四季報(東洋経済):そーせいグループ【業績予想更新(2020/05/26)】:(5/28up) ・2020年12月期予想:売上高10,300百万円、営業利益 ,500百万円、税前利益 ,650百万円、当期利益1,550百万円、1株益 20.1円 ・2021年12月期予想:売上高11,300百万円、営業利益1,000百万円、税前利益1,100百万円、当期利益1,300百万円、1株益 16.8円 0287山師さん@トレード中2020/05/28(木) 18:03:56.01ID:bhuRII5U0 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。 成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。 ・・・ ※SOSEIの成長相場の動向:今回の下押しでの調整相場(2/17:新年最高値2217、3/13最安値1051)は順調に推移しました。笑。 2019/12/30 (終値2171) 売残高__7200 買残高_7743600 ・(12/30安値2162) ※2019年大納会 2020/_1/31 (終値1932) 売残高__3500 買残高_7134700 ・(1/30安値1825) ※1/15: Presentation 2020/_2/28 (終値1645) 売残高_12800 買残高_5606500 ・(2/28:安値1590) ※2/13::決算 2020/_3/27 (終値1288) 売残高_12600 買残高_3487900 ・(3/23安値1063) ※3/25:株主総会 2020/_4/24 (終値1417) 売残高_13600 買残高_3325000 ・(4/22安値1345) ※5日・25日線再GC(4/9) 0288山師さん@トレード中2020/05/28(木) 18:04:19.39ID:bhuRII5U0 2020/_5/_1 (終値1577) 売残高_20300 買残高_3389600 ・(4/28安値1436) ※4/30: QVM149欧州承認勧告 2020/_5/15 (終値1687) 売残高_17500 買残高_3234400 ・(5/8; 5/11安値1500) ※5/13:第1四半期決算 ※一目均衡表3役好転(5/15) 2020/_5/22 (終値1794) 売残高_14300 買残高_3362800 ・(5/18安値1722) ※5日・75日線再GC(5/18) ※9週・13週線再GC(5/19) 2020/_5/25 (終値1802) 5日線1815.40( -0.74%) 25日線1573.00(+14.56%) (安値1791) 2020/_5/26 (終値1795) 5日線1814.40( -1.07%) 25日線1587.76(+13.05%) (安値1782) ※25日・75日線再GC(5/26) 2020/_5/27 (終値1792) 5日線1801.60( -0.53%) 25日線1602.04(+11.86%) (安値1750) 2020/_5/28 (終値1764) 5日線1789.40( -1.41%) 25日線1615.84( +9.17%) (安値1726) 0289山師さん@トレード中2020/05/28(木) 18:04:37.40ID:bhuRII5U0 更なる成長の黎明期、今回はコロナショックにて、信用需給が大きく改善し、振るいは順調に推移しましたね。笑。 新型コロナの感染拡大も収束中。笑。成長戦略は着実に進捗。笑。次なる成長ステージが楽しみですね。笑。 0290山師さん@トレード中2020/05/28(木) 18:51:23.15ID:UruJufjEx zoom
切り忘れ オナwww
http://pr9.work/0/kimuraha0291山師さん@トレード中2020/05/28(木) 19:30:44.28ID:ZS4X5wmoa ちょい待って下さいよぉ… 0292山師さん@トレード中2020/05/28(木) 19:33:26.42ID:1kGYT63YM そろそろか 0293山師さん@トレード中2020/05/28(木) 19:39:27.43ID:qhFeg2eLM もう待てねぇ 0294山師さん@トレード中2020/05/28(木) 19:48:13.11ID:1kGYT63YM 震えてきた エナジア爆誕の瞬間に立ち会える奇跡 0295山師さん@トレード中2020/05/28(木) 20:40:45.94ID:zZ/s5XEJ0 PTSなにこれ 漏れてるの? 0296山師さん@トレード中2020/05/28(木) 21:04:15.45ID:h0gZiSQx0>>295 これって悪材料? 0297山師さん@トレード中2020/05/28(木) 21:08:29.70ID:zZ/s5XEJ0 馬鹿が見るー 0298山師さん@トレード中2020/05/28(木) 21:23:15.63ID:h0gZiSQx0 逆だぼけ 0299山師さん@トレード中2020/05/28(木) 21:27:31.67ID:TsDw0Fc20 みんな楽しそうでなによりですな(^∇^) 0300山師さん@トレード中2020/05/28(木) 21:30:16.82ID:bhuRII5U0 ちなみに MTL-CEBPA Presentations: ・・・ ※MiNA Therapeutics: "Announces Research Collaboration with AstraZeneca in Metabolic Diseases". Completion of these studies, AstraZeneca will have the option to negotiate a license agreement to further develop saRNA molecules. (1/7) ※MiNA Therapeutics: "Announces Initiation of Phase I Clinical Study of MTL-CEBPA in Combination with anti-PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumours". TIMEPOINT Study. (3/3) ※Advanced Therapies 2020: "Small activating RNAs as a novel approach for immunotherapy": David Blakey, MiNA Therapeutics. (4/1 Presented) ※Clinical Cencer Research: "MTL-CEBPA, a small activating RNA therapeutic up-regulating C/EBP-α, in patients with advanced liver cancer: a first-in-human, multi-centre, open-label, phase I trial". Results.(5/1 Published) ※World Journal Gastroenterology: "Radiofrequency Combined with Immunomodulation for Hepatocellular Carcinoma: State of the art and innovations." RFA, checkpoint blockade and MTL-CEBPA. (5/7 Published) ※City of Hope: "Two Groundbreaking Drugs will Combat COVID-19 and its Deadliest Symptoms": MTL-CEBPA, Rossi and Habib Plan to Extend the Liver Cancer Trial to COVID Patients. (5/7) ※ASGCT: "Therapeutic saRNAstargeting CEBPA in Myeloid Cells. A Potential Immunomodulatoryswitch for Anticancer Therapy": MTL-CEBPA can potentially act as an immuno-modulatory switch. (5/12 Presented) ・・・ 0301山師さん@トレード中2020/05/28(木) 21:30:35.68ID:bhuRII5U0 ※MiNA Therapeutics: "MiNA Therapeutics Announces Publication of Phase I Liver Cancer Data in Clinical Cancer Research and Provides Update on Clinical Development and Drug Discovery Programs". (5/27) Announced today the publication of data from its Phase I liver cancer trial, OUTREACH, in Clinical Cancer Research. It is the first publication in which a small activating RNA treatment (MTL-CEBPA) demonstrated clinical benefit. Publication and OUTREACH Study Update: The publication in Clinical Cancer Research summarizes the results from MiNA’s Phase I, open-label, dose escalation and dose expansion trial of MTL-CEBPA, OUTREACH, in adults with advanced Hepatocellular Carcinoma (HCC). Overall, MTL-CEBPA was well-tolerated and demonstrated pharmacodynamic target engagement, meeting the primary endpoint of the study. Furthermore, a reduction of suppressive immune cells in the tumour microenvironment as well as initial signs of potential synergistic efficacy when combined with standard of care tyrosine kinase inhibitors in HCC could be observed. These encouraging Phase I data validate the targeting of C/EBP-α as a novel therapeutic strategy in cancer and prompted a Phase Ib study further evaluating MTL-CEBPA in combination with sorafenib in HCC. Enrolment for the Phase Ib part of the OUTREACH trial was completed in Q1 2020 and initial results will be presented during a poster session at the forthcoming American Society of Clinical Oncology (ASCO) on Friday, May 29, 2020. The framework for a subsequent Phase II clinical trial is currently being designed with the objective of initiating this next stage of clinical development in the second half of 2020. 0302山師さん@トレード中2020/05/28(木) 21:30:55.66ID:bhuRII5U0 ↓ ※ASCO 2020 Virtual Scientific Program Meeting (5/29-5/31) Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary: Poster Session: [Abstract #:4601] "Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)." Conclusions: MTL-CEBPA + sorafenib is well tolerated with an acceptable safety profile. This study has confirmed signals of objective response to the combination treatment in TKI naïve HCC patients with viral aetiology, warranting expanded development in these patients. Updated efficacy and safety data will be presented. Clinical trial information: NCT02716012. https://meetinglibrary.asco.org/record/186586/abstract
・・・ ※TIDES 2020: "Small Activating RNA to CEBPa in Patients with Hepatocellular Carcinoma": Nagy Habib, MiNA Therapeutics. (9/18 12:00 Presenting) ※Keystone Symposium: Myeloid Cells and Innate Immunity in Solid Tumors: "MTL-CEBPA - Next Generation Immunotherapy Targeting Myeloid Cell Differentiation": Nagy Habib. (9/24 17:00 Presenting) ・・・ 0303山師さん@トレード中2020/05/28(木) 21:39:19.86ID:TsDw0Fc20 ちなみに…笑 0304山師さん@トレード中2020/05/28(木) 21:40:10.02ID:TsDw0Fc20 みんな機嫌良くてなによりだよね笑 0305山師さん@トレード中2020/05/28(木) 22:10:43.33ID:QmW0qvVu0 こんなに待たせやがって、逃げ場くらいつくれただろ 今の株価が中途半端過ぎる 0306山師さん@トレード中2020/05/28(木) 22:27:57.26ID:TsDw0Fc20>>305 え?今絶好の逃げ場じゃん笑 なに言ってんのwwwウケるwww 0307山師さん@トレード中2020/05/28(木) 22:30:57.29ID:bhuRII5U0 AZD4635 Presentations: ・・・ ※AACR: Translational Cancer Mechanisms and Therapy: "Adenosine Signaling is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response". AZD4635 in a Phase I Trial, 4 of which. (3/23 Published) ※AstraZeneca Q1 2020 Results: Q1 NME (Prostate Cancer, Phase II): AZD4635, Imfinzi+AZD4635, Oleclumab+AZD4635. "What’s Next: Phase I/II New Medicines, Selected: AZD4635 (Solid Tumours)." (4/29) ※Clinical Cencer Research May: "Adenosine Signaling is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response": AZD4635, Landscape of Adenosine Signaling in Cancer. (5/1 Publication) ※Immuno Therapy of Cancer: "Conversion of ATP to Adenosine by CD39 and CD73 in Multiple Myeloma can be Successfully Targeted Together with Adenosine Receptor A2A Blockade." AZD4635. (5/14 Published) ・・・ ※AstraZeneca Press Releases: "AstraZeneca Advances the Science of Cancer Medicine with Practice-Changing Data at the ASCO20 Virtual Scientific Program". (5/13) "A Phase I, Open-label, Multicenter Study to Assess the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of AZD4635 both as Monotherapy and in Combination in Patients with Advanced Solid Malignancies: Results from Prostate Cancer Patients" ・(Abstract #5518. ・Poster #99 Poster Session - Genitourinary Cancer - Prostate, Testicular, and Penile.) 0308山師さん@トレード中2020/05/28(木) 22:31:05.70ID:TsDw0Fc20 うわっ、改めて見たら俺今日こんなに書き込んでたんだね笑 だってテンション上がるじゃん?こんなの笑 明日からがもっと楽しそうだけどwww 0309山師さん@トレード中2020/05/28(木) 22:31:18.07ID:bhuRII5U0 ↓ ※ASCO 2020 Virtual Scientific Program Meeting .(5/29-5/31: Virtual) Genitourinary Cancer - Prostate, Testicular, and Penile: Poster Discussion Session: [Abstract #: 5518]: "A Phase I, Open-label, Multicenter Study to Assess the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of AZD4635 both as Monotherapy and in Combination in Patients with Advanced Solid Malignancies: Results from Prostate Cancer Patients (NCT02740985)." Conclusions: In mCRPC pts, AZD4635 alone or in combination with durva was tolerable and associated with clinical benefit. A mCRPC phase II trial is ongoing with continued exploration of predictors of response to treatment. Clinical trial information: NCT02740985. https://meetinglibrary.asco.org/record/187566/abstract0310山師さん@トレード中2020/05/28(木) 22:31:40.18ID:bhuRII5U0 ・・・ ※AACR:. "Clinical Pharmacology of AZD4635: Integration of PK data from Cancer Patients and Healthy Volunteer Clinical Trials to Provide Dosing Recommendations". (6/22 9:00: Virtual) ・https://www.abstractsonline.com/pp8/#!/9045/presentation/11313 ※AACR:. "Targeting A2aR (AZD4635) in Mouse Pten-Deficient Prostate Cancer". (6/23 9:05-9:15: Virtual) ・https://www.abstractsonline.com/pp8/#!/9045/presentation/6910 ※AstraZeneca Q2 2020 Results: (7/30) ・・・ 0311山師さん@トレード中2020/05/28(木) 22:45:44.14ID:p/e3ga2+M 病院行け 0312山師さん@トレード中2020/05/28(木) 23:05:09.20ID:X701C73WM きたな おめ 0313山師さん@トレード中2020/05/28(木) 23:12:33.37ID:2+Ib5JrId ホルダーおめ 0314山師さん@トレード中2020/05/28(木) 23:30:25.60ID:bhuRII5U0 ・・・
※Medical Journal, Danmark: "New Triple Inhaler Approved in the EU". (5/26) Enerzair Breezhaler, the first triple combination therapy to target asthma patients, has been approved for use in the EU. That's a good idea, says asthma specialist Charlotte Ulrik. The treatment consists of a solid combination of the three active substances indacaterol (LABA), glycopyrronium (LAMA) and mometasone (ICS) in capsules administered by a powder inhaler. “These are ingredients that we know, just as we have seen before. The new is the triple combination of the drugs and the sensor that is integrated into the inhaler, ”says Charlotte Ulrik, professor and consultant at the Pulmonary Medicine Department, Hvidovre Hospital. Ulrik also points out that the treatment of asthma is moving towards the doctor first trying to get good asthma control with a triple treatment before turning up for treatment with high dose ICS. “For those patients who have suffered from more severe non-treated asthma who are being treated with LABA / ICS, the new guidelines from ERS / ATS and GINA recommend that a LAMA be added. This means that Enerzair Breezhaler targets the group of patients who are not well-treated on two-drug treatment, ”explains Ulrik, who is excited about the inhaler's technical addition. “The sensor that sends data to an app on the patient's smartphone, tablet or the like is a really good idea. Because we know that for many asthma patients, remembering medicine is a challenge. Therefore, a smartphone app with the option of being reminded to take its medication may be a good idea for quite a few patients. It is really well thought that you have integrated a technical device in this inhaler, ”points out the professor. The sensor in the breez holder includes a microchip, a microphone, bluetooth, antenna and a battery. The sensor is attached to the inhaler base where it collects data on the patient's medication usage as the sensor records every single dose administered. Based on the patient's medication usage, personalized data is presented in the corresponding app, which can help the patient optimize adherence to the treatment and thus, in all likelihood, his asthma control. 0315山師さん@トレード中2020/05/28(木) 23:30:33.67ID:bhuRII5U0 Smart solution for patients: In addition to the technical measures, Professor Ulrik is also pleased with the prospect of having the opportunity in the future to prescribe a triple combination for patients with more severe asthma. “As a starting point, I would like to have as many different treatment options, devices and different combinations as possible. Furthermore, like Trelegy, Enerzair Breezhaler is a treatment that the patient only needs to take once a day, and it will suit many people, ”says Ulrik and continues: “Some patients will find it nice to have a single daily inhalation because they feel less sick when they only have to take their medication once a day. Then there will be a beep from one's smartphone when it is time to take today's dose that is even being recorded. It is a good thing because it is not always easy to remember to take the medicine, especially during periods of few symptoms. ” Enerzair breezhaler is indicated for adult patients with symptoms that are insufficiently controlled by a maintenance combination of a long-acting beta2 agonist and a high dose of an inhaled steroid and who have experienced one or more asthma exacerbations the previous year. Enerzair breezhaler is a maintenance treatment that aims at symptom control by preventing exacerbations and maintaining the best possible lung function. The treatment becomes available as 114 µg / 46 µg / 136 µg hard capsule inhalation powder.